Researchers has demonstrably advanced this course of an novel therapy for cardiac amyloidosis, employing the compound. Early trial information indicates promising benefits for those suffering by this severe illness. This effort highlights the company’s commitment to managing significant medical demands in the heart space. Attruby: BridgeBio's No